Among them, programmed death ligand 1 (PD-L1) as an immune checkpoint protein in the cancer immune cycle is highly expressed in the low-risk group, which may indicate that tumor cells in low-risk patients rely on the PD-1/PD-L1 signaling pathway to evade immune monitoring, and PD-1 monoclonal antibodies may have a good effect on patients in the low-risk group. Here, CD274 is linked to cancer.